SelectEvidenceTM: Complete Cybersecurity Medical Device Risk Assessment Platform
Transform the way you carry out risk assessments for your connected medical devices. SelectEvidenceTM from Nova Leah provides manufacturers with an intelligent, automated, and traceable approach to medical device cybersecurity risk management.
Accelerated Analysis
Proprietary algorithms inform
accelerated analysis, greatly
cutting the time needed to
manage risk.
Decision Support
For every vulnerability identified,
specific and actionable
suggested mitigations are
provided.
Continuous Monitoring
& Alerts
Scanning over 180K
vulnerabilities in real-time,
harnessing automation for
24/7 peace of mind.
Enterprise Level Reporting
Multi-level access and
reporting available for
compliance transparency
and visibility.
Standards-Based
Linked to industry standards,
leverage key repositories
for controls threats and
vulnerabilities.
Auto-Ingest SBOMs
Simple and automated ingestion
of each SBOM makes it easy
and fast to start monitoring
and managing risk.
Accelerate
Premarket cybersecurity risk analysis
Save Time
Postmarket continuously monitoring vulnerabilities
Leveraging SelectEvidenceTM as an integral part of your product development lifecycle for security risk assessment ensures your connected medical devices meet FDA Premarket Submission and Postmarket Management guidelines.
Nova Leah
Nova Leah is a world leader in the provision of cybersecurity solutions for medical device manufacturers and healthcare providers. With operations in the US and in Ireland, Nova Leah’s software helps connected medical device manufacturers meet cybersecurity compliance requirements throughout the entire product lifecycle.
